What Are The Best Treatments For Chronic Hives?

Follow Drugslib on

By Dennis Thompson HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

FRIDAY, July 18, 2025 — Hives can drive a person crazy, covering parts of the body with maddeningly itchy welts.

Now, a new evidence review has identified the most effective treatments for people who suffer from chronic hives.

The injectable antibody drug omalizumab and a yet-to-be-approved pill called remibrutinib are among the most effective treatments for reducing the itch and swelling of hives, researchers reported July 15 in the Journal of Allergy and Clinical Immunology.

Another injectable antibody drug called dupilumab also showed promise in reducing hives, researchers said.

A cheaper and time-tested drug, cyclosporine, is also effective but carries a higher risk of kidney damage, high blood pressure and other side effects, researchers added.

“This first comprehensive analysis of all advanced treatment options for chronic urticaria (hives) provides a clear and evidence-based ‘menu of treatment options’ for patients and their clinicians to choose from,” senior researcher Dr. Derek Chu, an assistant professor of medicine at McMaster University in Ontario, Canada, said in a news release.

Hives occur when skin cells release histamine as part of an allergic reaction, according to Harvard Medical School. The biochemical causes tiny blood vessels to leak, and the leaking fluid forms into swollen welts.

For the review, researchers pooled data from 93 previous clinical trials involving more than 11,000 participants. The team examined more than 40 treatment options for hives, considering both how effective they are and any safety issues they might have.

Omalizumab and remibrutinib rated highest in terms of effectiveness and safety, results show.

Omalizumab is an injectable drug that blocks the action of Immunoglobulin E, an antibody that promotes allergic reactions. The pricey drug is sold under the brand name Xolair, but earlier this year the U.S. Food and Drug Administration (FDA) approved a biosimilar form called Omlyclo developed by the drug company Celltrion.

Remibrutinib is currently under FDA review. Developed by Novartis, the pill has been shown in clinical trials to help more than half of patients with chronic hives. It works by blocking an enzyme cascade that prompts release of histamine.

The evidence review also found that the injectable drug dupilumab (Dupixent) is effective against hives. Approved in 2017, this drug works by blocking two inflammatory proteins, interleukin-4 and interleukin-13.

A much cheaper drug, cyclosporine, is effective against hives “but may be among the most harmful in increasing the frequency of any adverse events,” researchers wrote.

The findings of this study will be used to help write new international clinical guidelines for treating hives, researchers said.

Sources

  • McMaster University, news release, July 15, 2025

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2025-07-19 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords